

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

Attorney's Docket Number

03715.0069

U.S. Application No.

09/673795

International Application. No.  
PCT/FR99/00957

International Filing Date  
April 22, 1999

Priority Date Claimed  
April 22, 1998

422 Rec'd PCT/PTO 20 OCT 2000

Title of Invention: MUTATED PEPTIDE COMPOUNDS, DERIVED FROM hsp70, USEFUL IN CANCER IMMUNOTHERAPY

Applicant(s) For DO/EO/US: Frédéric TRIEBEL and Catherine GAUDIN

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

- 09/673795-102000
1. [X] This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
  2. [ ] This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
  3. [ ] This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
  4. [X] A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
  5. [X] A copy of the International Application as filed (35 U.S.C. 371(c)(2))
    - a. [ ] is transmitted herewith (required only if not transmitted by the International Bureau).
    - b. [X] has been transmitted by the International Bureau.
    - c. [ ] is not required, as the application was filed in the United States Receiving Office (RO/US).
  6. [X] A translation of the International Application into English (35 U.S.C. 371(c)(2)).
  7. [X] Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).
    - a. [ ] are transmitted herewith (required only if not transmitted by the International Bureau).
    - b. [ ] have been transmitted by the International Bureau.
    - c. [ ] have not been made; however, the time limit for making such amendments has NOT expired.
    - d. [X] have not been made and will not be made.
  8. [ ] A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
  9. [X] An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
  10. [ ] A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. [ ] An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. [X] An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. [ ] A FIRST preliminary amendment.  
[ ] A SECOND or SUBSEQUENT preliminary amendment.
14. [ ] A substitute specification.
15. [ ] A change of power of attorney and/or address letter.
16. [X] Other items or information:
  - a. [x] Copy of cover sheet of WIPO PCT publication with English-language abstract.
  - b. [x] Sequence Listing (2 pages)

09/673795

PCT/FR99/00957

03715.0069

17. [X] The following fees are submitted:

Basic National Fee (37 CFR 1.492(a)(1)-(5)) \$860.00

Search Report has been prepared by the EPO or JPO.....\$860.00

International preliminary examination fee paid to

USPTO (37 CFR 1.482).....\$690.00

No international preliminary examination fee paid to

USPTO (37 CFR 1.482) but international search fee

paid to USPTO (37 CFR 1.445(a)(2)).....\$760.00

Neither international preliminary examination fee

(37 CFR 1.482) nor international search fee

(37 CFR 1.445(a)(2)) paid to USPTO.....\$1,000.00

International preliminary examination fee paid to USPTO

(37 CFR 1.482) and all claims satisfied provisions

of PCT Article 33(1)-(4).....\$ 100.00

ENTER APPROPRIATE BASIC FEE AMOUNT = \$860.00

Surcharge of \$130.00 for furnishing the oath or declaration later than

[ ] 20 [ ] 30 months from the earliest claimed priority date

(37 CFR 1.492(e)).

Claims	Number Filed	Number Extra	Rate	
Total Claims	46 -20=	26	X \$18.00	\$468.00
Independent Claims	3 - 3=		X \$80.00	\$
Multiple dependent claim(s) (if applicable)			+ \$270.00	\$

TOTAL OF ABOVE CALCULATIONS = \$1328.00

Reduction by 1/2 for filing by small entity, if applicable. Verified

Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28)

SUBTOTAL = \$1328.00

Processing fee of \$130.00 for furnishing the English translation later

than [ ] 20 [ ] 30 months from the earliest claimed priority date

(37 CFR 1.492(f)).

TOTAL NATIONAL FEE = \$1328.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The

assignment must be accompanied by an appropriate cover sheet

(37 CFR 3.28, 3.31). \$40.00 per property + \$

TOTAL FEES ENCLOSED = \$40.00

Amount to be

refunded \$

charged \$

- a. [X] A check in the amount of \$1368.00 to cover the above fees is enclosed.

- b. [ ] Please charge my Deposit Account No. \_\_\_\_\_ in the amount of

\$

to cover the above fees. A duplicate copy of this sheet is enclosed.

- c. [X] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 06-0916. A duplicate copy of this sheet is enclosed.

The Commissioner is hereby authorized to charge any other fees due under 37 C.F.R. \$1.16 or \$1.17 during the pendency of this application to our Deposit Account No. 06-0916.

SEND ALL CORRESPONDENCE TO:

Finnegan, Henderson, Farabow

Garrett &amp; Dunner, L.L.P.

1300 I Street, N.W.

Washington, D.C. 20005-3315

EPC/FPD/dvz

ERNEST F CHAPMAN

Reg. No. 25, 961

Submitted: October 20, 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

09/673795

Atty. Docket No: 03715.0069

In re patent application of

TRIEBEL, FREDERIC et al.

Serial No. 09/673,795

Filed: October 20, 2000

For: MUTATED PEPTIDE COMPOUNDS, DERIVED FROM hsp70, USEFUL IN CANCER  
IMMUNOTHERAPYSTATEMENT TO SUPPORT FILING AND SUBMISSION IN  
ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825Assistant Commissioner for Patents  
Washington, D.C. 20231

Box SEQUENCE

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not include new matter;

2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same; and

3. all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United


09/673795-102000

Serial No. 09/673,795

States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,

June 7, 2001  
Date

  
James A. Coburn

**HARBOR CONSULTING**  
Intellectual Property Services  
1500A Lafayette Road  
Suite 262  
Portsmouth, N.H.  
800-318-3021

09673795.102600

MUTATED PEPTIDE COMPOUNDS, DERIVED FROM  
hsp70, USEFUL IN CANCER IMMUNOTHERAPY.

5 The present invention relates to a method for  
identifying peptide compounds derived from hsp70 which  
have at least one mutation or one modification with  
respect to the natural hsp70 sequence, said compounds  
bringing about a T response specific for tumors, and to  
10 the peptide compounds which can be obtained with said  
method. The invention also relates to the use of these  
peptide compounds for performing repeated immunization  
in an individual so as to break down immune tolerance  
for the corresponding natural peptide (nonmutated). The  
peptide compounds are useful for manufacturing a  
15 medicinal product intended in particular for treating  
cancer, optionally in combination with any agent which  
causes tumor cell stress.

For a long time, researchers have attempted to  
find mechanisms for stimulating the immune rejection of  
20 tumors, starting from the hypothesis that antigens,  
which can be used as targets, are expressed at the  
surface of the cancerous cells. The delicate balance  
between tumor growth and regression has been the  
subject of multiple theories, in particular with regard  
25 to the role of the immune system. Immunosurveillance is  
an attractive theory according to which tumors are  
destroyed at the very first stage of their development  
by immune defense mechanisms. For example, the  
observation that many tumors are infiltrated by  
30 lymphoid cells appears to be a sign of favorable  
prognostic.

However, the incidence of cancers in immuno-  
deficient individuals is not significantly higher than  
in the general population. This fact has been  
35 correlated by experiments carried out on immuno-  
deficient mice (nude mice). Specifically, these mice  
bred under sterile conditions, develop no more tumors  
than the mice with a wild-type genotype. Thus, it is

09673795-102000

commonly accepted today that the very slightly increased risk of the appearance of cancers in immunodeficient individuals is directly correlated with the incidence of viral infections (oncogenic viruses). This suggests that the immune response would intervene by limiting virus dissemination and by recognizing the cancerous cells carrying viral antigens. When an oncogenic virus integrates the genome of the host cell, there is expression by said cells of modified proteins which are capable of constituting antigenic targets.

However, with regard to tumors of nonviral origin, the major problem for the immune defenses comes from the fact that there are no flagrant antigenic differences with normal cells. This is why these tumors are thought to escape, to a certain degree, immunosurveillance. Some antigens specifically expressed by nonviral tumors have been demonstrated. For example, the CALLA protein (Common Acute Lymphoblastic Leukemia Antigen), which is normally expressed in hematopoietic cells and repressed in normal mature B lymphocytes, is overexpressed in lymphoblasts. Thus, antigenic proteins of tumors are not foreign to the organism and are naturally present in some normal cells.

Thus, the thing which distinguishes antigenic proteins, and which can be recognized by the immune defenses, is a mutation, a modification (for example a posttranslational modification of an amino acid) or a differential distribution, or alternatively an overexpression. It is clear that the recognition of said proteins by lymphocytes is reduced because of their intrinsic presence in normal cells (negative clonal selection). Persons skilled in the art must therefore resolve this problem in order to find an effective mechanism for activating the immune defenses with respect to cancerous cells. The challenge is all the greater given that the concentration of the antigens is low and that their presentation by MHC molecules is sometimes inadequate.

The object is thus to identify antigenic peptides specific for tumors, which should be capable of effectively stimulating the immune defenses in vivo, in particular cytotoxic T lymphocytes. These peptides  
5 can be used as vaccines optionally comprising costimulators such as cytokines or lymphokines.

Farace et al, (1997), has demonstrated that the induction of the inflammatory response in delayed-type hypersensitivity and at the site of the vaccine in an  
10 immunized patient, originates from the recruitment of only a few T-cell clones. These cells correspond to the lymphocytes which have infiltrated into a tumor and have already been amplified, before immunization. Thus, tumor antigens can be used to locally recruit and  
15 amplify T lymphocytes specific for tumors. The cells activated in vivo can be further amplified by administering IL-2. Specifically, Kumar A. et al (1996) has shown that T-cell clone activity is induced in the blood, and in the tumors, of patients receiving IL-2.

It has been difficult to isolate and to amplify the clones of cytotoxic T lymphocytes (CTLs) specific for renal carcinoma cells, Bernhard et al, (1994) and Brouwenstijn et al, (1996). This difficulty originates from the lack of proliferation of the tumor-  
25 infiltrating lymphocytes (TILs), particularly in cells of renal carcinoma (RCC), Alexander et al, (1993). However, some results indicate that RCCs might be immunogenic in vitro since these tumors are often greatly infiltrated by T lymphocytes, in particular by  
30 TCR  $\alpha/\beta^+$  DR $^+$  Th1-polarized lymphocytes, Angevin et al, (1997), and because of the relatively high level of response (15 to 20%) to certain immunotherapy protocols, Rosenberg et al, (1992).

An antigen, which is recognized by RCC  
35 autologous CTLs, has been identified by Gaugler et al, (1996). This antigen is encoded by a gene, termed RAGE 1, which is expressed in many tumors but which is absent from normal adult tissues, except those of the

09673795.102000

retina. It is clear that the use of RAGE 1 for cancer immunotherapy presents problems since this might generate reactions of autoimmune rejection of the retina. Preparations comprising the combination hsp-peptide isolated from cancerous cells or from cells infected with viruses confer immune protection with respect to the tumors and to the infected cells, Blachere et al, (1997). Other documents, such as WO 97/10001, WO 97/06828, WO 97/26910 or Tamura et al, (1993) and (1997), relate to the treatment of neoplastic cells with hsp70/cancerous cell-derived peptides complexes. These documents of the prior art disclose the capacity of hsp70 to absorb like a sponge the peptides from cells. The isolation of hsp70 originating from cancerous cells makes it possible to identify multiple protein fragments of tumors, which may potentially be antigenic. It has now been found that mutations or modifications in the hsp70 protein exist which are expressed in tumors, and that such mutations or modifications prove to be immunogenic. Since it is known that hsp70 may be overexpressed in tumors, said peptides are useful for inducing a breakdown of tolerance against hsp70.

Thus, no document of the prior art discloses or suggests the present invention as defined below.

#### **Description of the invention**

The present invention relates to a method for identifying peptide compounds derived from hsp70 which have at least one mutation or one modification with respect to the natural hsp70 sequence, said compounds bringing about a T response specific for tumors, comprising the following steps:

- a) PCR-amplifying a DNA fragment encoding hsp70, obtained from one or more tumor(s),
- b) cloning the DNA obtained in step a) into a vector capable of replicating in a bacterium,



- c) sequencing said fragment in each bacterial colony obtained after culturing the bacteria of step b), and identifying the mutation(s) in hsp70,
- d) determining the immunogenicity of the mutated peptide fragments among those identified in step c). Advantageously, step d) consists of an Elispot assay. It is possible to simply test the immunogenicity of the peptide fragments which have an anchoring sequence for a given HLA molecule (see below, "reverse immunology" method).

The peptide fragments to be tested in step d) can easily be obtained by chemical synthesis using general knowledge in the technical field.

- In the context of the invention, the term "hsp70" is intended to mean both hsp70-1 and hsp70-2. The Elispot assay is widely described in the documents of the prior art. For example, Herr et al, (1998) relates to an Elispot method for detecting and quantifying CD8 + T lymphocytes secreting TNF- $\alpha$ . In summary, MultiScreen-HA plates (Millipore, Bedford, MA) are coated with an anti-TNF- $\alpha$  antibody (clone 195; Boehringer Mannheim), and CD8 + T lymphocytes are added in the presence of antigenic peptides. The secreted TNF- $\alpha$  is detected with a rabbit anti-TNF- $\alpha$  antibody (Serotec, Oxford, UK), a biotin-coupled rabbit anti-IgG antibody (Boehringer Mannheim) and the biotin-avidin-peroxidase complex (Vector, Burlingame, CA). The number and surface area of the zones in which the cytokine is present are determined automatically by computer (Herr et al, (1997). Other documents, such as Herr et al, (1996) materials and methods section, paragraph 2, pages 132 to 135, and Scheibenbogen et al, (1997) page 933, disclose this method, and are also incorporated into the description by way of reference.

- The invention also relates to a method for revealing artificial point mutations or modifications which can increase the immunogenicity of the mutated

peptide compounds derived from hsp70, wherein it comprises the following steps:

- a) determining fragments which have a sequence of approximately 9 to 10 amino acids comprising an anchoring motif for a given HLA molecule,
  - b) introducing an additional point mutation or modification at residues 4, 5, 6, 7 or 8,
  - c) determining the immunogenicity of the peptide fragments obtained in step b).
- 10 Preferably, step c) consists of an Elispot assay. This method is well known to persons skilled in the art. There may also be incorporated, by way of reference, into the description, the teachings which are to be found at the following Internet address:
- 15 [www.bimas.dcrt.nih.gov/molbio/hla\\_bind/](http://www.bimas.dcrt.nih.gov/molbio/hla_bind/)
- This method makes it possible to determine any artificial point mutation or modification, (not present in human tumors) which would be capable of improving the active principle (the immunogenic mutated peptide),
- 20 using the so-called "reverse immunology" method. Based on the knowledge of the amino acid sequence of a protein, such as hsp70, it is possible to predict which of the peptides can bind to an HLA pocket, whatever its specificity (HLA-A2, HLA-A1, HLA-B7, etc.), then to
- 25 test these peptides in vitro for their capacity to bind effectively to the HLA allele under consideration, and then to introduce a point mutation or modification into the amino acids at certain positions which are critical for affinity. The BIMAS computer program enables such a
- 30 prediction to be obtained. The general rules regarding the amino acids involved in anchoring to HLA molecules are given in Parker et al, (1992 and 1994) and Rammensee et al, (1995). This information is incorporated by way of reference into the description.
- 35 Of course, the method according to the invention is not limited to the use of the BIMAS program, and can be used with any equivalent program.

09673795-102000

Another aspect of the invention relates to a peptide compound which can be obtained using a method described above. This compound is characterized by the fact that it comprises a sequence of at least 8 consecutive amino acids of hsp70, by the fact that it has at least one mutation or one modification with respect to the natural hsp70 sequence, and by the fact that it brings about a specific T response.

A specific aspect relates to a peptide compound having at least 80% homology with the amino acids between positions 286 and 294 of hsp70.

Preferably, the amino acid at position 293 is isoleucine, leucine, valine, alanine, glycine or phenylalanine, more particularly isoleucine. The preferred peptide compounds of the invention have at least one of the following sequences:

- SEQ ID No. 1: 286-SLFEGIDIIY-294
- SEQ ID No. 2: 286-SLFEGIDIYT-295

Said compounds can also comprise unnatural amino acids which may or may not be equivalent to the natural amino acids.

The term "peptide compound" is intended to mean an entity consisting at a minimum of a peptide fragment of hsp70 as defined above, or of a series of said peptide fragments, and having optionally one or more other elements other than natural or unnatural amino acids. The purpose of these elements is to chemically or physically protect said peptide fragments, and/or to promote their absorption by the body, and/or their administration, and/or their bioavailability. For example, this protection enables the peptides to reach their targets without undergoing the action of diverse proteases present in the body. Such chemical modifications may also increase the affinity of an antigenic peptide for HLA-A2 molecules, and allow an increased effectiveness of the vaccine in vivo to be obtained, Rosenberg et al, (1998).

Said elements can be, for example:

- Protective chemical groups known to persons skilled in the art, which react with the NH<sub>2</sub> and/or COOH ends of a peptide, this modification not significantly lowering the immunogenic nature of the peptide.
- Chemical groups which improve the effectiveness of the vaccine in vivo.
- The lipids or fatty acids which are covalently bonded to the peptide fragments so as to form peptide compounds termed lipopeptides. Palmitic acid is one example among others, Vitiello et al, (1995), which is incorporated into the description by way of reference.
- A carrier protein for said peptide fragments which possesses restriction sites and enables the intact peptide fragments to be conveyed to their sites of action in the body.

A second aspect of the invention relates to the DNA fragments encoding the peptide fragments mentioned above. The term "DNA fragments" is intended to mean single-stranded or double-stranded DNA, cDNA and/or RNA fragments. The nucleotide sequence corresponding to the amino acid sequence of said peptide fragments can vary so as to comprise all the various possible codons for a given amino acid according to the principle of degeneracy of the genetic code. A subject of the present invention is also a vector for expressing a peptide fragment, containing an abovementioned DNA fragment fused to a promoter which is strong and effective in eukaryotic and/or in prokaryotic cells, in particular in human cells. The vector can be viral, a plasmid vector or a pseudovector, and can comprise selection markers and express immunological adjuvants such as cytokines and/or lymphokines.

The invention also relates to dendritic cells loaded with peptide compounds, and dendritic cells transformed with the expression vector expressing the peptide

fragments. These cells can also be macrophages. Nestle et al, (1998), discloses a vaccination method which consists in loading the dendritic cells taken from a patient with antigenic peptides (in culture in vitro), and injecting them into the lymphatic system of this same patient. This publication is incorporated into the description by way of reference.

The subject of another aspect of the invention is a pharmaceutical composition comprising a peptide compound, or a mixture of peptide compounds, according to the invention and a pharmaceutically acceptable vehicle. This composition can also comprise one or more immunological adjuvants, in particular factors which are cytotoxic for tumors.

The invention also relates to a pharmaceutical composition comprising an expression vector as mentioned above and a pharmaceutically acceptable vehicle, or a DNA fragment according to the invention, or alternatively the cells indicated above, and a pharmaceutically acceptable vehicle.

A further aspect of the invention relates to a combination product comprising at least one peptide compound as claimed in the invention and at least one agent which induces cellular stress, for simultaneous or separate use, or for use spread out over time, intended for treating cancer. Preferably, said agent can be capable of inducing overexpression of heat shock proteins, in particular hsp70. Advantageously, this agent is an apoptosis inducer, selected in particular from DNA-damaging agents and glucocorticoid receptor ligands, or from pro-apoptotic second messengers.

The combination product can comprise a viral vector which has a gene which encodes an enzyme for activating said pro-apoptotic agents, in particular thymidine kinase.

The expression "agent which induces cellular stress" refers to any agent which is capable of inducing overexpression of heat shock proteins, in

particular hsp70. These agents can be in particular apoptosis-inducers. The expression "apoptosis-inducing agent" is intended to mean any substance which directly or indirectly affects the viability of a cell.

5 Said apoptosis-inducing agent of the present invention can be selected in particular from DNA-damaging agents and glucocorticoid receptor ligands, or from pro-apoptotic second messengers.

10 These agents can be selected preferably from those commonly used in the treatment of cancer. Thus, said pro-apoptotic second messenger is in particular selected from the following compounds:

- glucocorticoid derivatives,
- from alkylating agents such as nitrogen mustards,
- 15 for example cyclophosphamide,
- platinum complexes, for example cisplatin,
- ethyleneimine derivatives, dimethanesulfonyl-alkane derivatives,
- piperazine derivatives,
- 20 - from topoisomerase inhibitors, such as topoisomerase 2 inhibitors, for example anthracyclines, epipodophyllotoxin such as etoposide, or topoisomerase-1 inhibitors, for example camptothecin derivatives,
- 25 - from antimetabolites, such as antifolates, for example methotrexate, antipurines, for example 6-mercaptopurine, or antipyrimidines, for example 5-fluorouracil,
- from antimitotic agents, such as vinca alkaloids
- 30 or taxoids such as taxotere,
- and from diverse cytolytic agents such as bleomycin, dacarbazine, hydroxycarbamide, asparaginase, mitoguanzone or plicamycin.

These antineoplastic agents are described in Actualité  
35 Pharmaceutiques No. 302 (Oct 1992) pages 38 to 39 and 41 to 43, incorporated into the description by way of reference.

000001-56262660

5

15

30

35

The pharmaceutical composition or combination product according to the invention can also comprise one or more immunological adjuvants, in particular agents which are cytotoxic for tumors. These products can comprise a pharmaceutical vehicle which is compatible with IV, subcutaneous, oral or nasal administration, and which is preferably selected from positively or negatively charged liposomes, nanoparticles or lipid emulsions.

The present invention also relates to the use of a peptide compound as claimed in one of claims 7 to 11, for manufacturing a medicinal product, in particular intended for treating cancer, particularly solid tumors, especially carcinomas, melanomas, neuroblastomas and neck and head cancers, preferably renal carcinomas. This medicinal product can be intended for immunization ex situ or in situ. The invention also relates to the use of said peptide compound for increasing, in culture medium, the tumor CTL population and/or inducing the secretion by said CTLs of cytotoxic factors, such as for example IL-2, IFN- $\gamma$  or TNF, and/or for stimulating the immune defenses, in particular so as to increase the tumor CTL population and/or induce the secretion by said CTLs of cytotoxic factors, such as for example IL-2, IFN- $\gamma$  or TNF.

Of course, the compositions and products of the invention can be used in combination with radiotherapy. Advantageously, the compositions and products of the invention can be taken advantage of to perform repeated immunization for the purpose of causing a breakdown of tolerance against the corresponding natural peptide (nonmutated) in a patient. Specifically, since it is known that hsp70 is or may be overexpressed in tumors, it is most advantageous to be able to immunize patients



against this protein. Immunization with the mutated peptides of this protein is capable of breaking down the tolerance of the immune system of patients with respect to hsp70 and consequently, of specifically  
5 stimulating cytotoxic and helper T lymphocytes against cancerous cells, whatever the type of cancer or of patient.

An additional aspect of the invention relates to a method for producing an antibody which binds to an  
10 hsp70 mutant, in particular to the hsp70-2 I-293 mutant, comprising the steps consisting in:

- a) immunizing a mammal with a peptide compound as claimed in the invention,
- b) isolating a monoclonal antibody which binds to  
15 hsp70-2-293, particularly to hsp70-2 I-293, in an immunological assay.

The present invention also comprises a monoclonal antibody which binds to hsp70-2-293, particularly to hsp70-2 I-293, and a method for detecting the  
20 hsp70-2-293 mutation or modification, in particular the hsp70-2 I-293 mutation or modification, in which the steps consist in:

- a) bringing a sample taken from an individual into contact with one said monoclonal antibody,
- 25 b) allowing the formation of the antibody/hsp70-2-293 complex,
- c) detecting hsp70-2-293 by means of a detectable label which is in the complex or which binds to the complex.

30 In a further embodiment, the present invention relates to a diagnostic kit comprising in particular one or more of said antibodies. This kit can in particular be used for detecting cancer and for the prognostic of established cancer in an individual. Finally, a subject  
35 of the invention is also a pharmaceutical composition comprising one or more of said monoclonal antibodies and a pharmaceutically acceptable vehicle. The present invention relates, in the same way, to the use of the

09623795.102000

above-mentioned pharmaceutical composition in medicine, for manufacturing a medicinal product, in particular for treating cancer, particularly for treating solid tumors, advantageously carcinomas, melanomas, neuroblastomas, and neck and head cancers, preferably renal carcinomas.

**Detailed description of the invention.**

The subject of the present invention thus makes it possible to stimulate the immune defenses by increasing the population of CTLs specific for tumors, and by inducing the secretion by said CTLs of cytotoxic factors. Such an amplification of the specific CTLs amounts to bringing about and to expanding a veritable army of cells which destroy tumors. Specifically, cytotoxic T lymphocytes play a specific role in antigen recognition, and infiltrate into even solid tumors. The activity of CTLs consists in recognizing the antigen combined with syngeneic class I MHC molecules. The CTLs and the target cell then form a bond via the CD8-TCR association with MHC I.

The steps of the cytotoxicity mechanism are as follows:

- Recognition, highly specific binding, and formation of the TCR-CD8-MHCI (antigenic peptide) ternary complex.
  - Secretion by CTLs of perforin and of various enzymes toward the target cell membrane.
  - Formation of channels in the target cell membrane by polymerization of the perforin by an enzyme, in the presence of calcium (polyperforin channels).
  - Passage of proteases and of toxins through the channels, and action inside the target cell.
  - Other toxic factors, such as TNF- $\alpha$ , lymphotoxin (TNF- $\beta$ ) and IFN- $\gamma$ , released by the CTLs bind to specific receptors of the target cell membrane.
- Apoptosis is then observed, characterized by the fragmentation of DNA, by budding of the cytoplasmic membrane, and by the disintegration of the cell into small fragments (apoptotic bodies).

- A subject of the invention is thus to supply the body with sufficient amounts of peptides which have a high immunogenic potential and are specific for tumors. Such peptide fragments are very rare, diluted among an infinite number of peptides, and difficult to identify. In fact, the binding of the peptides with the MHC molecule is located in an invagination which has a specific topology and specific physicochemical properties, which vary depending on the nature of the amino acids involved. Thus, a peptide (approximately 9 amino acids) binds to an MHC as a function of the nature of these side chains and of its complementarity with the MHC molecule cavity. This association with the MHC takes place in specific intracellular organisms. Antigenic proteins are generally degraded to peptides in proteasomes (ubiquitous multicatalytic proteinase complexes) before the transport of said peptides into the rough endoplasmic reticulum (RER). The MHC I synthesis and the assembly with the peptides takes place in the RER. Then, the antigen-MHC I complexes are exported to the surface of the cells via the Golgi apparatus. It is thus understood why only certain peptides can bind to the MHC I. With regard to the peptides of the present invention, it has been demonstrated (see below) that they have a very low dissociation constant  $K_d$  (very strong association). In this respect, they make it possible to activate the immune system effectively, in particular the CTLs.
- The CTLs specific for RCC can be isolated from the tumor-infiltrating lymphocytes (TILs) of a patient. At least 80% of the RCC TILs are activated  $DR^+$   $LAG-3^+$   $CD8^+$  cells, Angevin et al. (1997). Subsequent to a short activation of these TILs in vitro, a response of Th1-polarized type was observed (secretion of IL-2 and of interferon  $\gamma$ , but not of IL-4). On the other hand, Finke et al, (1993) has published that the apparent lack of activity of TILs in vivo is due to the poor functioning of the various regulatory cascades in these

09673795-102000

cells. However, among the 5 CTLs described in the present invention, clone 2A11 (TCRBV1J1S6) is particularly advantageous since it is amplified at the tumor site and represents up to 3% of the TCR  $\alpha/\beta^+$  5  
TILs. In addition, this clone recognizes an antigen specific for tumors which is presented by HLA-Cw16, Angevin et al. (1997). This thus demonstrates that the HLA-C molecules are capable of presenting elements at the tumor site in this patient.

10 hsp70 is encoded by the duplicated locus (hsp70-1, hsp70-2) located in the MHC region at 92 Kb from the C2 gene in the direction of the telomer, Milner et al, (1990). This DNA segment is termed class IV region, and comprises at least 7 genes involved in  
15 inflammatory responses and stress responses, Gruen, (1997). The two intron-lacking genes (hsp70-1 and hsp70-2) encode an identical protein of 641 amino acids. There are a few sequence differences in the promoter region and complete divergence in the  
20 untranslated 3' region. Using a probe specific for hsp70-2, a rise in the amount of mRNA (2.4 Kb) has been shown subsequent to a heat shock. The hsp70-2 probe has made it possible to detect a small amount of 2.4-Kb mRNA in the constitutive RNA of the cell lines of the  
25 RCC tumor and in frozen surgical samples of said tumor. The reason for which the allogenic cell line HLA-A2<sup>+</sup> RCC, which expresses low levels of hsp70-2 mRNA, was not killed by CTL 11C2, may be due to the difference observed in target sensitization assays between the  
30 mutated peptides and the wild-type decapeptide 286-295 ( $5 \times 10^{-11}$  M and  $5 \times 10^{-8}$  M, respectively, for maximum half-lysis). The transcription and overexpression of wild-type hsp70-2 in COS-7 cells induce the secretion of TNF by CTL 11C2.

35 It is known that hsps are nonpolymorphic molecules which do not differ in their primary structure among normal tissues and cancers, or among normal cells and cells infected with viruses. Thus, the

002207.54464

For the remainder of the description and for the examples, reference will be made to the figures whose legend is given below.

### Legends

**Figure 1: Specific lytic activity of clone 11C2 against the RCC-7 autologous cell line.**

The cytotoxicity of the 11C2-CTLs with respect to the RCC-7 cell line was assayed by the standard chromium release assay at various effector/target ratios (E/T ratio). The inhibition of the cytotoxic activity of 11C2 was assayed after several preincubations of the CTLs for two hours with the anti-HLA class 1 mAb (monoclonal antibody) indicated, at a predetermined saturation concentration.

**Figure 2: Secretion of TNF by the 11C2-CTL clone during stimulation with the RCC-7 autologous cell line.**

5000 CTLs were incubated with 20,000 RCC-7 cells. The amount of TNF was measured after culturing for 20 hours, by assaying the toxicity of the supernatants with TNF-sensitive WEHI-164 cells (clone 13). The inhibition of the secretion of TNF was assayed after preincubation of clone 11C2 for two hours with the anti-class 1 HLA mAb as indicated.

**Figure 3: Cytotoxicity of the 11C2 CTLs on multiple RCC allogenic cell lines.**

11C2 was assayed on the RCC-7 autologous line and on multiple RCC allogenic cell lines (RCC-8, RCC-9, RCC-10 and RCC-11) in a standard chromium release assay at the E/T ratio indicated. The HLA molecules shared with RCC-7 are indicated in brackets.

**Figure 4: Stimulation of the 11C2 CTL by the cells transiently cotransfected with the autologous HLA-A\*0201 cDNA and the A18 cDNA.**

The 11C2 CTL was added 48 hours after cotransfection. The TNF contained in the supernatants was estimated 20 hours later by assaying its toxicity on WEHI-164 cells (clone 13). The stimulatory cells comprise the RCC-7 cell line as a positive control and

COS-7 cells which are nontransfected or transfected with the HLA\*0201 cDNA alone as a negative control.

**Figure 5: Location of the epitope region of hsp70-2 recognized by the 11C2 CTL.**

- (A) The total length of the hsp70-2 cDNA is represented schematically in black and white. 5' UT and 3'UT correspond to the 5' and 3' untranslated regions respectively. The coding region (in black) begins with the translation start site (ATG codon) and corresponds to nucleotide + 1. The multiple truncated clones obtained from the A18 cDNA are represented in gray. The A18 cDNA begins at nucleotide 577 of the coding region. The mutated nucleotide is marked with an asterisk (position 877).
- (B) Illustrates the stimulation of the 11C2 CTL by COS-7 cells temporarily cotransfected with the autologous HLA-A\*0201 cDNA and with each of the various truncated A18 cDNAs. The transfected cells were incubated for 24 hours with 5000 11C2 CTLs, and the amount of TNF was measured 20 hours later. The control stimulatory cells comprise COS-7 cells which are non-transfected or transfected with the A18 cDNA alone, as a negative control, and cotransfected with the A18 and A\*0201 cDNAs as a positive control.

**Figure 6: Lysis by 11C2 CTLs of the autologous cell line transformed with EBV and incubated with the peptides encoded by hsp70-2**

- 2000 cells transformed with EBV and labeled with <sup>51</sup>Cr were incubated for 1 hour in the presence of the hsp70-2 peptides indicated, at multiple concentrations. The 11C2 CTL was then added at an effector/target ratio (E/T) of 31/1. Chromium release was measured 4 hours later. The asterisks indicate the mutated amino acid.

**Figure 7: Induction of HLA-A2 expression on T2 cells by the hsp70-2 antigenic peptides.**

T2 cells were incubated at 26°C for 16 hours in serum-free medium, with or without peptide at a concentration of 20 µM. Next, the peptides were again added, and the cells were incubated at 37°C. At 30-minute or one-hour intervals, the cell pellets were collected and the change in HLA-A2 expression was analyzed by flow cytometry with an anti-HLA-A2 mAb (MA2.1). The amino acid sequences of the peptides are represented, the mutated amino acid is represented by an asterisk.

**Figure 8: Northern Blot Analysis**

The total cytoplasmic RNA (15 µg), derived from the RCC-7 tumor (row No. 1), from the RCC-7 cell line (No. 2), and the autologous cell line transformed with EBV (No. 3), is maintained at 37°C (subrow C) or treated by heat shock for 2 hours at 40°C (subrow HS), was fractionated on denaturing formaldehyde/agarose gel and transferred onto Hybond-N<sup>+</sup> nylon membrane. The Northern Blot was hybridized with the probes consisting of a fragment specific for hsp70 and for the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA. The migration position of the 28s and 18s RNAs is given. The approximately 2.4-Kb hsp70-2 transcript is indicated by an arrow above the 18s RNA and above the GAPDH mRNA.

**Figure 9: Elispot assay**

This figure shows that the mutation or modification brings about a highly increased immunogenicity power. Mutated hsp is the peptide compound according to the invention, hsp nat is the corresponding natural peptide (nonmutated), MP is the positive control (very immunogenic peptide of the "matrix protein" and T2 is the negative control (cells not stimulated by the peptide).



The studies of the present invention have allowed the isolation of RCC-CTL clones originating from TILs (tumor-infiltrating lymphocytes) obtained in three different experiments and using two experimental conditions (use of IL-2 or of IL-2 + IL-7 + IL-12). Between the 20<sup>th</sup> and 30<sup>th</sup> day, these cells, belonging to the cultures which show considerable lysis of the autologous cell line of the RCC-7 tumor, were cloned by a limiting dilution. Out of 8 clones obtained by this protocol, 5 were selected as a function of their distinct TCR phenotype. All the clones are TCR  $\alpha/\beta^+$  CD8<sup>+</sup> CD4<sup>-</sup> cytotoxic cells, and produce TNF when they are stimulated by autologous cells of the tumor. The blocking effect of the anti-class 1 mAb WC/32 showed that the cytotoxic activity is MHC I molecule-restricted (Figure 1). The lytic activity of clone 11C2 was blocked by mAb MA2.1 specific for HLA-A2 (Figure 2). This result suggests that HLA-A2 is the presentation molecule for 11C2, and that 11C2 recognizes the autologous cells of the tumors (Figure 3).

#### **Identification of the cDNA of the antigen recognized by 11C2 CTLs**

In order to identify the gene encoding the antigen a genetic approach was used, comprising the transfection of a cDNA library originating from the RCC tumor into COS-7 cells with the cDNA encoding the HLA-A2 presentation molecule, Seed B. (1987). The expression vector used contains the SV40 origin of replication, which allows a considerable multiplication of the episomes of the transfected plasmid, and thus high expression of the transfected genes. A cDNA library was used which was constructed in the pCDNA I expression vector using the RNAs originating from the RCC-7 cell line. This library was divided into 400 parts of 200 recombinant plasmids, and each part was cotransfected in duplicate with the pCDNA I autologous

HLA-A\*0201 construct, into COS-7 cells. The COS-7 cells were then assayed for their capacity to stimulate the production of TNF by clone 11C2. 48 hours later, the cotransfected COS-7 cells were incubated overnight with 11C2, and the TNF concentration in the supernatant was determined through its cytotoxic action on WEHI cells. The amount of TNF in the supernatants is below 5 pg/ml, except for two pairs (40 and 45 pg/ml) of duplicated experiments. The second screening was carried out by transfecting the COS cells with 100 parts of 20 recombinant plasmids originating from the extraction of double positives. Finally, a third screening led to two cDNA clones (termed A8 and B65) being isolated, which make it possible to transfer the antigen expression into the HLA-A\*0201<sup>+</sup> COS-7 cells. The results obtained with the A18 cDNA clone is presented in Figure 4.

The sequence of the longest cDNA (A18) is 1.9 Kb with 100% homology to the nucleotides from 577 to 2876 of the hsp70-2 cDNA, except for a mutation at position 877 (an adenine in place of a thymine). Position +1 is the translation start site of hsp70-2, Milner et al, 1990.

With the aim of identifying the entire length of the hsp70-2 cDNA, and in order to verify whether the mutation is only present at the tumor site, we performed a PCR (hsp70-2 is an intron-lacking gene) on the DNA originating from the extraction of RCC-7 cells and of B cells transformed with EBV and of PHA blasts. A single 2-Kb product, corresponding to nucleotide -36 to 1974, was obtained in each of the cases, and was subcloned into the vector pcDNA I for sequencing and expression. 4 of the 7 DNA clones, obtained from the tumor fragment, have the mutation. For the cells transformed with EBV and the blasts, none of the 14 DNA sequences analyzed carries the mutation. Thus, the mutation is present only on a chromosome in the tumor cells and is absent in the normal cells.

**Identification of the antigenic peptide**

In order to delimit the minimum nucleotide region encoding the antigenic peptide, multiple truncated cDNAs were obtained from the A18 cDNA clone.

5 The use of exonuclease III made it possible to gradually generate deletions starting from the 3' end of the cDNA (Figure 5). These cDNA fragments were cotransfected into COS-7 cells with the autologous HLA-A\*0201 cDNA. A minimum coding nucleotide region was

10 located between nucleotides 730 and 944. The truncation in the region carrying the single mutation specific for the tumor abolishes recognition by 11C2 CTLs. Peptides carrying the HLA-A\*0201 binding motif were sought in this region, and among the 18 peptides assayed, only 2

15 (the nonapeptide SLFEGIDIV, amino acids 286 to 294, and the decapeptide SLFEGIDIYT, amino acids 286 to 295) carrying the mutant isoleucine residue at position 8 were recognized. Maximum half-lysis was obtained with only  $5 \times 10^{-11}$  M of the decapeptide, compared to  $5 \times 10^{-7}$

20 M of the nonapeptide (Figure 6). 11C2 CTL also recognizes the wild-type decapeptide 286-295 (SLFEGIDFYT), with a maximum half-lysis of  $5 \times 10^{-8}$  M, but not the wild-type nonapeptide 286-294 (Figure 6).

**25 Binding of the hsp70-2 peptide fragments to HLA-A2**

Antigenic peptides which can bind HLA-A2 can regulate positively the expression of HLA-A2 molecules in T2 cells, Nijman et al. (1993). The binding capacity

30 of the hsp70-2 286-295 decapeptides (mutated and wild-type) was compared to that of the nonapeptide 286-294. The binding of these two decapeptides is stable over a period of 4 hours at 20  $\mu$ M without showing any difference between the mutant and wild-type forms (Figure 7). The hsp70-2 nonapeptides are less

35 effective, but their binding is comparable to that of the MART-1<sub>27-35</sub> peptide to HLA-A2. As could be expected, no effect was observed for the control peptide HLA-B7 (see Figure 7).

09673795-102000

**Northern Blot analysis**

A probe specific for the hsp70-2 locus, including the 3' untranslated region, was used to examine the expression of the hsp70-2 gene. A 2.4-Kb mRNA was detected in the autologous cells transformed with EBV. Similarly, a low level of expression was observed in the untreated RCC-7 cells and in the frozen surgical samples of RCC-7 (Figure 8). Low levels of expression were also observed in other tumors, in particular in melanomas, neuroblastomas, adenocarcinomas of the colon and bladder tumor fragments.

**Example 1: Establishing RCC cell lines.**

The cell lines were established from the cells of renal carcinoma RCC, as described previously by Angevin et al, 1997. In summary, the primary tumors were obtained from untreated patients who had undergone a radical nephrectomy in our institution. Patient 7 (HLA-A2, -A29 -B44, -B51 -Cw15, -Cw16) is a 54-year-old male individual with a metastatic RCC. After surgery and enzymatic digestion, fresh cell suspensions from the RCC tumors were seeded in a culture medium composed of Dulbeccos' Modified Eagle Medium (DMEM), penicillin (50 IU/ml), streptomycin (50 µg/ml), 1% of 200 mM L-glutamine, 1% of 200 mM sodium pyruvate, 10% of fetal calf serum (FCS) and 1% of Ultrosor G (Gibco-BRL, Paisley, UK). This medium is termed, in the remainder of the document, "RCC medium". All the tumor cell lines were maintained in this RCC medium. The RCC-7 cell line was obtained from the primary tumor of patient 7.

**Example 2: Cells and culture media**

The EBV autologous cell line was obtained after infection of PBMCs of patient 7. The cell line transformed with EBV was maintained in RPMI 1640 (Gibco-BRL), supplemented with 10% of FCS.

WEHI-164 clone 13, a TNF-sensitive mouse fibrosarcoma cell line, was diligently provided by Benoit Van Den Eynde (Ludwig Institute for Cancer Research, Brussels, Belgium), and was cultured in RPMI 1640 (Seromed, Biochrom KG, Berlin, Germany) supplemented with L-glutamine, sodium pyruvate, antibiotics and 5% of FCS, at a concentration of 0.01 to 0.05  $\times 10^6$  cells/ml. The mutant human cell line CEM  $\times$  721.174.T2 (T2), Salter et al, (1989), was maintained in RPMI-1640 supplemented with 10% of FCS. This cell line was diligently provided by Pierre Langlade (Pasteur Institute, Paris, France). All cell cultures were maintained in an atmosphere saturated with water and with a 5% CO<sub>2</sub> content.

**Example 3: Establishing the TIL cell lines**

The TILs, originating from the tumor suspensions, were inoculated in flasks containing RPMI 1640, penicillin, streptomycin, 1% of L-glutamine, 1% of sodium pyruvate and 8% of human AB serum (Institut Jacques Boy S.A., Reims, France), termed complete medium. The TILs were seeded at the same concentration in complete medium supplemented with 10 IU/ml of rIL-2, 50 IU/ml of rIL-7 (Sanofi, Toulouse, France) and 10 IU/ml of rIL-12 (Genetics Institute, Cambridge, MA), for three days. From the 3<sup>rd</sup> day onward, the TILs were fed using the complete medium with 30 IU/ml of rIL-2, 50 IU/ml of rIL-7 and 10 IU/ml of rIL-12. The phenotype and the cytotoxic activity of the TIL cell lines were characterized after 14 and 21 days of stimulation.

**Example 4: Monoclonal antibodies (mAbs), serological agent and phenotypic analysis**

The mAbs conjugated either to fluorescein (FITC) or to phycoerythrin (PE), and directed against the TCR  $\alpha/\beta$ , CD3 (Leu4), CD4 (Leu3a), CD8 (Leu8), CD80 (B7.1) and HLA DR (L249), were purchased from Becton

Dickinson (Mountain View, CA). CD56 (NKH1A) originates from Coultronics (Hialeah, FL). The TILs were characterized by double immunostaining, by incubating the cells for 30 min at 4°C with FITC- or PE-mAb. The flow cytometry analysis was carried out on a FACScan (Becton Dickinson) and using the Cellquest software. The laboratory ascites were W6.32 (anti-HLA-A/B/C), MA2.1 (anti-HLA-A2 and -B17) and B1.23.2 (anti-HLA-B/C), and were selected for the functional and immunofluorescence experiments, at predetermined saturation concentrations up to a final dilution of between 1/200 and 1/2000.

**Example 5: Cloning of the TIL cell lines**

After culturing for 3 weeks, the lymphocytes were cloned by diluting them to the limit. The cloning was performed between 600 and 0.6 cells/well, in 96-well plates containing RPMI medium supplemented with 8% of human AB serum, 30 IU/mL of rIL-2 and 3% of TCGF. At the bottom of the wells, a feeder layer was cultured consisting of irradiated autologous tumor cells ( $1 \times 10^4$ /well), of irradiated allogenic lymphocytes ( $8 \times 10^4$  per well) and of irradiated cells transformed with EBV ( $2 \times 10^4$ /well). The clones were fed three times per week with the complete medium containing rIL2 and TCGF. The immunological phenotype and the cytotoxicity were characterized for the cloned cells.

**Example 6: Cytotoxicity assay**

The cytotoxicity assays were carried out using the standard 4-hour chromium release assay, as described above, Angevin et al, (1997). In summary,  $2 \times 10^3$   $^{51}\text{Cr}$ -labeled target cells were incubated for 4 hours at 37°C, with the effector cells at various E/T ratios, in a final volume of 200  $\mu\text{l}$ . With regard to lysis inhibition by the mAbs, the target cells were preincubated for two hours in the presence of saturating concentrations of mAb, before adding the

effector cells. At the end of the incubation, 40 µl of supernatant were transferred to Lumaplate 96 solid scintillation plates (Packard Instruments, Meriden, CT), were dried overnight and counted in a beta-radioactivity counter (Packard Instruments).

**Example 7: Cloning and expression of the HLA molecules**

The class 1 HLA alleles were cloned using the PCR method described by Ennis et al, (1990), with a few slight modifications. The total RNA was prepared from the RCC-7 cell line using RNA<sup>B</sup> (Bioprobe Systems). The first cDNA strand was synthesized with an oligo(dT) probe and reverse transcriptase (Invitrogen). The cDNA was used as a matrix for a 30-cycle PCR amplification with the following probes:

- 5P2-H (5'-GGGCAAGCTTGGACTCAGAATCTCCCCAGACGCCGAG-3'),  
SEQ ID No. 3

- 3P2-X (5'-GCCCTCTAGATCTCAGTCCCTCACAAGGCAGCTGTC-3'),  
SEQ ID No. 4

These probes correspond to the consensus sequences of the 5' and 3' untranslated regions, respectively, of the class 1 alleles. These probes are identical to the HLA-5P2 and HLA-3P2 probes described above, Ennis et al. (1990), except for the cloning site (the Sal I and Hind III sites for 5P2, and the Hind III and Xba I sites for 3P2, respectively, were replaced. The PCR products were digested with Hind III and Xba I, and ligated into the plasmid pcDNA I (Invitrogen). These constructs were transfected into E. coli MC 1061/P3. The plasmid DNA was then extracted from several colonies using QIAGEN columns (Qiagen). The DNA sequencing was carried out using the "ABI PRISM Dye Terminator cycle sequencing ready reaction kit" (Applied Biosystems) and an automatic DNA sequencer. The sequences were compared to the class I HLA nucleotide sequences available in the databases.

**Example 8: Construction of the cDNA library**

The poly(A)<sup>+</sup> RNA was extracted from the RCC-7 cell line using the mRNA isolation system (Fast Track kit 2.0, Invitrogen), respecting the manufacturer's instructions. The first cDNA strand was synthesized using AMV reverse transcriptase with an oligo-dT probe containing a Not I site at its 5' end. The RNA-cDNA hybrid created by the synthesis of the first strand was transformed into double-stranded cDNA with DNA polymerase I in combination with Rnase H and DNA ligase from E. coli. Next, T4 DNA polymerase was used to produce a blunt cleavage in the cDNA. BstX I linkers were added, and the size of the cDNA was obtained by fractionation on agarose gel. The cDNA of desired size (longer than 800 nucleotides) was ligated into the vector pcDNA I cleaved with BstX I/Not I, and the suitable E. coli strain (MC1061/P3) was transformed. For the screening experiments, the plasmid DNA obtained from some bacterial colonies was prepared according to the following protocol: 100 or 200 colonies, cultured in LB-agar medium (with 30 µl/ml of ampicillin and 10 µl/ml of tetracyclin), were seeded in 2 ml of LB medium and incubated overnight at 37°C. The plasmid DNA was extracted using the alkaline lysis method, Birnboim et al, (1979), and was resuspended in 30 µl in 10 mM Tris-1 mM EDTA, pH 7.5, containing 20 µl/ml of RNase A. The plasmid DNA concentration was adjusted to 40 ng/µl.

**Example 9: Transfection of COS-7 cells and screening of transfectants**

The transfection experiments were carried out by the "DEAE-dextran-chloroquin method, Brichard et al, (1993). Three days before transfection, the COS-7 cells were seeded in 96-microwell plates at the concentration of  $5 \times 10^3$  cells/well, in 150 µl of RPMI medium containing 20% of fetal calf serum. For the transfection, the medium was replaced with 30 µl of DEAE-Dextran/DNA mixture. These mixtures were prepared



for double transfections in microwells by adding sequentially:

- 200 ng of plasmid DNA originating from the cDNA library,
- 5 - 200 ng of plasmid pcDNA I/HLA-A\*0201,
- 25  $\mu$ l of 150 mM NaCl, 10 mM Tris, pH 7.4 (termed TBS buffer),
- 35  $\mu$ l of TBS containing 1 mg/ml of DEAE-Dextran (Pharmacia Biotech Europe GmbH, Saclay, France).

- 10 The cells were incubated with this mixture plus 105  $\mu$ l of DMEM supplemented with 10% of non-complemented "NuSerum" (Becton Dickinson) and 100 mM of chloroquin (Sigma-Aldrich Chimie SARL, Saint Quentin Fallavier, France), for 30 minutes at room temperature.
- 15 Next, the cells were incubated for 4 hours at 37°C under a 5% CO<sub>2</sub> atmosphere. After incubation, the medium was removed, and the cells were incubated for 2 min in 1x PBS containing 10% of a solution of dimethyl sulfoxide. The cells were washed once with 1x PBS, and
- 20 incubated in RPMI containing 10% of FCS for 48 hours. The medium was then removed and the cells were washed once with 1x PBS. 5000 CTLs were added to the wells in 100  $\mu$ l of RPMI containing 10% of FCS. After 20 hours, the supernatant was collected and its TNF content was
- 25 determined by assaying its cytotoxicity on WEHI-164 clones 13 in an MTT(3-[4,5-dimethylthiozole]-2,5-diphenyltetrazolium bromide (Sigma-Aldrich) colorimetric assay, as described previously, Traversari et al, (1992). With regard to the inhibition
- 30 of the secretion of TNF by the mAbs, the target cells were preincubated for 2 hours in the presence of a saturating concentration of mAbs, before adding the effector cells for a further 20 hours.

35 **Example 10: PCR assay for isolating the entire length of hsp70-2**

The genomic DNA was extracted from the RCC-7 cell line with DNAzol™ (Life Technologies). 1  $\mu$ l of DNA

09673795.102000

was used for a PCR reaction using Taq DNA polymerase (Perkin Elmer). The following probes were used:

- the hsp70-2A probe, 5'-GGGCAAGCTTAGTCT-CAGAGCGGAGCCAAC-3'

5 (nucleotides -36 to -18, sense), SEQ ID No. 5,

- the hsp70-2B probe, 5'-GCCCTCTAGAGTCCCAACA-GTCCACCTCAA-3'

(nucleotides 1955 to 1974, antisense), SEQ ID No. 6.

These probes contain the Hind III and Xba I restriction sites, respectively. The conditions for the PCR were 98°C for 1 min, followed by 30 amplification cycles (98°C for 15 sec, 65°C for 1 min, 72°C for 2 min, with a final extension for 10 min at 72°C). The PCR product obtained was digested with Hind III and Xba I and purified on absorbent glass beads (Geneclean), and was then subcloned into the Hind III and Xba I sites of the expression vector pcDNA I for sequencing and cotransfection, with HLA-A\*0201, into the COS-7 cells.

20 **Example 11: Identification of the minimum nucleotide coding region for the antigenic peptide**

The A18 cDNA was isolated from the cDNA library manufactured from the expression vector pcDNA I. The plasmid was digested with Sph I and Xba I, before treatment with exonuclease III in order to generate gradual deletions starting from the 3' end of the A18 cDNA. In order to obtain a considerable number of truncated cDNA clones, the "Exo Mung Bean Deletion Kit" (Stratagene) was used. After ligation, the bacterium E. coli MC1061/P3 was transformed with the truncated cDNAs. The plasmid DNA was extracted from each clone, and then sequenced and cotransfected, with HLA-A\*0201 into the COS-7 cells.

35 **Example 12: Peptide synthesis and peptide recognition assay**

In the screening assay, the peptides used were synthesized by "PepSet technology" (Chiron

09673795.102000

Technologies, Suresnes, France). For the functional assays, the peptides were synthesized on solid phase using F-moc (temporary NH<sub>2</sub>-terminal protection), and were purified by preparative HPLC. The analytical HPLC indicates that the peptides are at least 95% pure. The lyophilized peptides were dissolved in 10 mM of DMSO in water, and conserved at -20°C. The peptides were used in a chromium release assay. 2000 autologous cells transformed with EBV, and labeled with <sup>51</sup>Cr, were incubated for 1 hour at 37°C on 96-well plates, with diverse concentrations of peptides, before adding 11C2 CTLs.

**Example 13: Peptide binding assay**

T2 cells, Nijman et al, (1993), were cultured 48 hours before the assay, in a serum-free AIM-V medium (Gibco-BRL). For the binding assays, the T2 cells (10<sup>6</sup>) were incubated at 26°C for 16 hours in the same medium in 0.8% of DMSO, with or without peptide at a concentration of 20 µM. Next, the peptides (20 µM) were again added, and the cells were incubated at 37°C. At 30-min or one-hour intervals, the cell pellets were collected, and the HLA-A2 expression level was monitored using the anti-HLA-A2 mAb (MA2.1).

**Example 14: RNA isolation and Northern Blot analysis**

The cells were either maintained at 37°C or underwent a heat shock at 42°C for 2 hours, before recovery by centrifugation. The total RNA was extracted by guanidinium isothiocyanate lysis, and was ultracentrifuged in cesium chloride. Samples of total RNA (15 µg) were fractionated in a denaturing gel containing 1% of formaldehyde-agarose, and were transferred onto Hybond-N+ nylon membranes respecting the manufacturer's instructions (Amersham France S.A., les Ulis, France). The Northern Blot was hybridized with a probe specific for hsp70-2 (nucleotides 1955 to 2159) and with the glyceraldehyde-3-phosphate

dehydrogenase (GAPDH) probe. All probes were labeled with [ $^{32}\text{P}$ ] dCTP (3000 Ci mmol $^{-1}$ ) using the Prime-IT $^{\text{TM}}$  II Random Primer labeling Kit (Stratagene). The hybridization was carried out at 45°C for 16 hours with the hsp70-2 probe (10 $^6$  cpm/ml) and the GAPDH probe (10 $^5$  cpm/ml). The membranes were washed twice with 2  $\times$  SSC at room temperature, once for 45 min with 2  $\times$  SSC/0.1% SDS at 62°C, and once at 62°C for 10 min with 0.1  $\times$  SSC, before autoradiography at 80°C for 11 days.

#### Example 15:      Elispot assay

CD8+ cells were isolated from HLA-A2-positive donors by negative immunomagnetic purification (using antibodies against CD4 and CD56 cells). 100,000 CD8+ cells were directly added to 100,000 HLA-A2.1-positive T2 cells loaded with 10 $^{-6}$  M of peptides, in 96-well plates in which the bottom is coated with nitrocellulose (Millipore). After stimulation of the CD8+ cells for 20 hours, an Elispot-IFN $\gamma$  assay was performed. The results are given in Table I below. The positive control is the peptide MP or "matrix protein", this being an influenza virus envelope protein which is very immunogenic in humans.

TABLE I: Elispot-IFN $\gamma$  assay results

	Donor 1	Donor 2	Donor 3	Donor 4	Donor 5
T2 alone	6	1	3.833	11.5	3.75
MP	57.25	31.33	13.33	26.5	16.5
mutated hsp	13	4.167	7.5	19.25	5.75
hsp nat	5	2.167	4	13.75	2

These results show that it is possible to induce human CD8 lymphocytes from healthy HLA-A2+ individuals with the preferred peptide compound of the invention (SEQ ID No. 1 and 2), but not with the corresponding nonmutated peptide. It clearly emerges that the mutation brings about a highly increased



## REFERENCES

- Alexander J.P., Kudoh S., Melsop K.A., Hamilton T.A., Edinger M.G., Tubbs R.R., Sica D., Tuason L., Klein E., Bukowski R.M., and Finke J.H. 1993, T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res. 53: 1380.
- 10 Angevin E., Kremer F., Gaudin C., Hercend T., and Triebel F. 1997, Analysis of T-cell immune response in renal cell carcinoma; polarization to type 1-like differentiation pattern, clonal T cell expansion and tumor-specific cytotoxicity, Int. J. Cancer 72: 431.
- 15 Bernhard H., Karbach J., Wolfel T., Busch P., Storkel S., Stockle M., Wolfel C., Seliger B., Huber C., Buschenfelde K. H.M.z., and Knuth A. 1994, Cellular immune response to human renal-cell carcinomas; definition of a common antigen recognized by HLA-A2 restricted cytotoxic T-lymphocyte (CTL) clones. International Journal of Cancer 59: 837.
- 20 Birnboim H.C., and Doly J. 1979. A rapid alkaline extraction procedure for screening recombinant plasmid DNA. Nucleic Acid, Res. 7:1513.
- 25 Blachere N.E., Li Z., Chandawarkar R.Y., Suto R., Jaikaria N.S., Basu S., Udono H., and Srivastava P.K. 1997. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocytes response and tumor immunity. J. Exp. Med. 186: 1315.
- 30 Brichard V., Pel A.V., Wölfel T., Wölfel C., Plaen E.D., Lethé B., Coulie P., and Boon T. 1993. The tyrosinase gene codes for an antigen recognized by

0000015662960

autologous cytolytic T lymphocytes on HLA-A2 melanomas.  
J. Exp. Med. 178: 489.

- 5 Brouwenstijn N., Gaugler B., Kruse K.M., Spek C.W.V.d.,  
Mulder A., Osanto S., Eynde B.J.V.d., and Schrier P.I.  
1996. Renal-cell carcinoma-specific lysis by cytotoxic  
T-lymphocyte clones isolated from peripheral blood  
lymphocytes and tumor-infiltrating lymphocytes. Inter.  
J. Cancer 68: 177.
- 10 Ennis P.D., Zemmour J., Salter R.D., and Parham P.  
1990. Rapid cloning of HLA-A,B cDNA by using the  
polymerase chain reaction: Frequency and nature of  
errors produced in amplification. Proc. Natl. Acad.  
15 Sci. 87: 2833.
- Even J., Lim A., Puisieux I., Ferradini L.,  
Dietrich P.Y., Toubert A., Hercend T., Triebel F.,  
Pannetier C., and Kourilsky P. 1995. T-cell repertoires  
20 in healthy and diseased human tissues analysed by  
T-cell receptor beta-chain CDR3 size determination:  
evidence for oligoclonal expansions in tumours and  
inflammatory diseases. Research Immunology. 146: 65.
- 25 Farace F., Angevin E., Poullion I., Leboullaire C.,  
Ferir G., Elias D., Escudier B., and Triebel F. 1997.  
T-cell receptor CDR3 size distribution analysis to  
evaluate specific T-cell response to cancer vaccines.  
Inter. J. Cancer 71: 972.
- 30 Finke J.H., Zea A.H., Stanley J., Longo D.L.,  
Mizoguchi H., Tubbs R.R., Wilttrout R.H., O'Shea J.J.,  
Kudoh S., Klein E., Bukowski R.M., and Ochoa A.C. 1993.  
Loss of T-cell receptor zeta chain and p56lck in  
35 T-cells infiltrating human renal cell carcinoma. Cancer  
Research, 53: 5613.

000001-5522360

- Gaugler B., Brouwenstijn N., Vantomme V., Szikora J.P., Spek C.W.V.d., Patard J.J., Boon T., Schrier P., and Eynde B.J.V.d. 1996. A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma. *Immunogenetics*. 44: 323.
- Genevee C., Diu A., Nierat J., Caignard A., Dietrich P.Y., Ferradini L., Roman-Roman S., Triebel F., and Hercend T. 1992. An experimentally validated panel of subsfamily-specific oligonucleotide primers (Valphal-w29/Vbetal-w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction. *Eur. J. Immunol.* 22: 1261.
- Gruen J.R., and Weissman S.M. 1997. Evolving views of the major histocompatibility complex. *Blood*. 90: 4252.
- Harris SR; Thorgeirsson UP, Tumor angiogenesis: biology and therapeutic prospects, *In Vivo* 1998 Nov-Dec; 12(6): 563-70
- Herr W, Protzer U, Lohse AW, Gerken G, zum Buschenfelde KHM, Wolfel T. Quantification of CD8+ Lymphocytes Responsive to Human Immunodeficiency Virus (HIV) Peptide Antigens in HIV-Infected Patients and Seronegative Persons at High Risk for Recent HIV Exposure. *Journal of InfDis* 1998; 178: 260-265.
- Herr W, Schneider J, Lohse AW, zum Buschenfelde KHM, Wolfel T. Detection and quantification of blood derived CD8+ T lymphocytes secreting tumor necrosis factor alfa in response to HLA-A2.1 binding melanomy and viral peptide antigens. *Journal of Imm Meth* 191; 1996; 131-142.
- Herr W, Linn B, Leister N, Wandel E, Meyer zum Buschenfelde KH, Wolfel T. The use of computer-assisted video image analysis for the quantification of CD8+ T



lymphocytes producing tumor necrosis factor spots in response to peptide antigens. *Journal of Imm Meth* 1997; 203: 141-152.

- 5 Kumar A., Farace F., Gaudin C., and Triebel F. 1996. Clonal T cell expansion induced by interleukin-2 therapy in blood and tumors. *J. Clin. Invest.* 97: 1219.
- 10 Locopo N; Fanelli M; Gasparini G, Clinical significance of angiogenic factors in breast cancer, *Breast Cancer Res Treat* 1998; 52(1-3): 159-73.
- 15 Maier JA; Morelli D; Lazzerini D; Menard S; Colnaghi MI; Balsari A, Inhibition of fibronectin activated migration of microvascular endothelial cells by IL1 alpha, TNF alpha and IF gamma, *Cytokine* 1999 Feb; 11(2): 134-9.
- 20 Milner C.M., and Campbell R.D., 1990. Structure and expression of the three MHC-linked hsp70 genes. *Immunogenetics.* 32:242.
- 25 Milner C.M., and Campbell R.D., 1992. Polymorphic analysis of the three MHC-linked hsp70 genes. *Immunogenetics.* 36:357.
- 30 Nestle F.O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., Burg G. and Schadendorf D., 1998. Vaccination of melanoma patients with peptide or tumor lysate-pulsed dendritic cells. *Nature Medicine* 3 328:332.
- 35 Nijman H.W., Houbiers J.G., Vierboom M.P., Burg S.H.v.d., Drijfhout J.W., D'Amato J., Kenemans P., Melief C.J., and Kast W.M. 1993. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. *Eur. J. Immunol.* 23(6): 1215.

- Pannetier C., Cochet M., Darche S., Casrouge A., Zoller M., and Kourilsky P. 1993. The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-like segments. Proc. Natl. Acad.Sci. USA 90:2472.
- Paper DH, Natural products as angiogenesis inhibitors, Planta Med 1998 Dec; 64(8): 686-95.
- Rosenberg S.A. 1992. The immunotherapy and gene therapy of cancer. Journal of Clinical Oncology 10: 180.
- Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., Topalian S.L., Restifo N.P., Dudley M.E., Schwartz S.L., Spiess P.J., Wunderlich J.R., Parkhurst M.R., Kawakami Y., Seipp C.A., Einhorn J.H. and D.E. White 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Medicine 3 321:327.
- Salter R.D., Norment A.M., Chen B.P., Clayberger C., Kresky A.M., Littman D.R., and Parham P. 1989. Polymorphism in the alpha3 domain of HLA-A molecules affects binding to CD8. Nature 338: 345.
- Scheibenbogen C, Lee KH, Stevanovic S, Witzens M, Willhauck M, Waldmann V, Nacher H, Rammensee HG, Keilholz U.
- Analysis of the T cell response to tumor and viral peptide antigens by an IFN-gamma ELISPOT assay. Int. Journal Cancer 1997; 932-936.
- Sheu JR; Fu CC; Tsai ML; Chung WJ, Effect of U-995, a potent shark cartilage-derived angiogenesis inhibitor, on anti-angiogenesis and anti-tumor activities. Anticancer Res 1998 Nov-Dec; 18(6A):4435-41.

2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 2044 2045 2046 2047 2048 2049 2050 2051 2052 2053 2054 2055 2056 2057 2058 2059 2060 2061 2062 2063 2064 2065 2066 2067 2068 2069 2070 2071 2072 2073 2074 2075 2076 2077 2078 2079 2080 2081 2082 2083 2084 2085 2086 2087 2088 2089 2090 2091 2092 2093 2094 2095 2096 2097 2098 2099 2100 2101 2102 2103 2104 2105 2106 2107 2108 2109 2110 2111 2112 2113 2114 2115 2116 2117 2118 2119 2120 2121 2122 2123 2124 2125 2126 2127 2128 2129 2130 2131 2132 2133 2134 2135 2136 2137 2138 2139 2140 2141 2142 2143 2144 2145 2146 2147 2148 2149 2150 2151 2152 2153 2154 2155 2156 2157 2158 2159 2160 2161 2162 2163 2164 2165 2166 2167 2168 2169 2170 2171 2172 2173 2174 2175 2176 2177 2178 2179 2180 2181 2182 2183 2184 2185 2186 2187 2188 2189 2190 2191 2192 2193 2194 2195 2196 2197 2198 2199 2200 2201 2202 2203 2204 2205 2206 2207 2208 2209 2210 2211 2212 2213 2214 2215 2216 2217 2218 2219 2220 2221 2222 2223 2224 2225 2226 2227 2228 2229 2230 2231 2232 2233 2234 2235 2236 2237 2238 2239 2240 2241 2242 2243 2244 2245 2246 2247 2248 2249 2250 2251 2252 2253 2254 2255 2256 2257 2258 2259 2260 2261 2262 2263 2264 2265 2266 2267 2268 2269 2270 2271 2272 2273 2274 2275 2276 2277 2278 2279 2280 2281 2282 2283 2284 2285 2286 2287 2288 2289 2290 2291 2292 2293 2294 2295 2296 2297 2298 2299 2300 2301 2302 2303 2304 2305 2306 2307 2308 2309 2310 2311 2312 2313 2314 2315 2316 2317 2318 2319 2320 2321 2322 2323 2324 2325 2326 2327 2328 2329 2330 2331 2332 2333 2334 2335 2336 2337 2338 2339 2340 2341 2342 2343 2344 2345 2346 2347 2348 2349 2350 2351 2352 2353 2354 2355 2356 2357 2358 2359 2360 2361 2362 2363 2364 2365 2366 2367 2368 2369 2370 2371 2372 2373 2374 2375 2376 2377 2378 2379 2380 2381 2382 2383 2384 2385 2386 2387 2388 2389 2390 2391 2392 2393 2394 2395 2396 2397 2398 2399 2400 2401 2402 2403 2404 2405 2406 2407 2408 2409 2410 2411 2412 2413 2414 2415 2416 2417 2418 2419 2420 2421 2422 2423 2424 2425 2426 2427 2428 2429 2430 2431 2432 2433 2434 2435 2436 2437 2438 2439 2440 2441 2442 2443 2444 2445 2446 2447 2448 2449 2450 2451 2452 2453 2454 2455 2456 2457 2458 2459 2460 2461 2462 2463 2464 2465 2466 2467 2468 2469 2470 2471 2472 2473 2474 2475 2476 2477 2478 2479 2480 2481 2482 2483 2484 2485 2486 2487 2488 2489 2490 2491 2492 2493 2494 2495 2496 2497 2498 2499 2500 2501 2502 2503 2504 2505 2506 2507 2508 2509 2510 2511 2512 2513 2514 2515 2516 2517 2518 2519 2520 2521 2522 2523 2524 2525 2526 2527 2528 2529 2530 2531 2532 2533 2534 2535 2536 2537 2538 2539 2540 2541 2542 2543 2544 2545 2546 2547 2548 2549 2550 2551 2552 2553 2554 2555 2556 2557 2558 2559 2560 2561 2562 2563 2564 2565 2566 2567 2568 2569 2570 2571 2572 2573 2574 2575 2576 2577 2578 2579 2580 2581 2582 2583 2584 2585 2586 2587 2588 2589 2590 2591 2592 2593 2594 2595 2596 2597 2598 2599 2600 2601 2602 2603 2604 2605 2606 2607 2608 2609 2610 2611 2612 2613 2614 2615 2616 2617 2618 2619 2620 2621 2622 2623 2624 2625 2626 2627 2628 2629 2630 2631 2632 2633 2634 2635 2636 2637 2638 2639 2640 2641 2642 2643 2644 2645 2646 2647 2648 2649 2650 2651 2652 2653 2654 2655 2656 2657 2658 2659 2660 2661 2662 2663 2664 2665 2666 2667 2668 2669 2670 2671 2672 2673 2674 2675 2676 2677 2678 2679 2680 2681 2682 2683 2684 2685 2686 2687 2688 2689 2690 2691 2692 2693 2694 2695 2696 2697 2698 2699 2700 2701 2702 2703 2704 2705 2706 2707 2708 2709 2710 2711 2712 2713 2714 2715 2716 2717 2718 2719 2720 2721 2722 2723 2724 2725 2726 2727 2728 2729 2730 2731 2732 2733 2734 2735 2736 2737 2738 2739 2740 2741 2742 2743 2744 2745 2746 2747 2748 2749 2750 2751 2752 2753 2754 2755 2756 2757 2758 2759 2760 2761 2762 2763 2764 2765 2766 2767 2768 2769 2770 2771 2772 2773 2774 2775 2776 2777 2778 2779 2780 2781 2782 2783 2784 2785 2786 2787 2788 2789 2790 2791 2792 2793 2794 2795 2796 2797 2798 2799 2800 2801 2802 2803 2804 2805 2806 2807 2808 2809 2810 2811 2812 2813 2814 2815 2816 2817 2818

- Traversari C., Van der Bruggen P., Luescher I.F., Lurquin C., Chomez P., Van Pel A., De Plaen E., Amar-Costesec A., and Boon T, 1992. A nonapeptide encoded by
- 5 human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. 176: 1453.
- Vitiello A., Ishioka G., Grey H.M., Rose R.,
- 10 Farness P., LaFond R., Yuan L., Chisari F., V., Furze J., Bartholomeuz R., and Chesnut R.W., 1995. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. J. Clin. Invest. 95 341:349.

000207-2672960

CLAIMS

1. A method for identifying peptide compounds derived from hsp70 which have at least one mutation or one modification with respect to the natural hsp70 sequence, said compounds bringing about a T response specific for tumors, comprising the following steps:
- 5 a) PCR-amplifying a DNA fragment encoding hsp70, obtained from one or more tumor(s),
- b) cloning the DNA obtained in step a) into a vector capable of replicating in a bacterium,
- 10 c) sequencing said fragment in each bacterial colony obtained after culturing the bacteria of step b), and identifying the mutation(s) in hsp70,
- d) determining the immunogenicity of the mutated peptide fragments among those identified in step c).
- 15 2. The method as claimed in claim 1, wherein step d) consists of an Elispot assay.
3. The method as claimed in either of claims 1 and 2, wherein the peptide fragments which have an anchoring sequence for a given HLA molecule are preferably tested.
- 20 4. The method as claimed in one of claims 1 to 3, wherein the peptide fragments to be tested in step d) are obtained by chemical synthesis.
- 25 5. A method for revealing artificial point mutations or modifications which can increase the immunogenicity of the mutated peptide compounds derived from hsp70, wherein it comprises the following steps:
- a) determining fragments which have a sequence of approximately 9 to 10 amino acids comprising an anchoring motif for a given HLA molecule,
- 30 b) introducing an additional point mutation or modification (for example a post-translational modification) at residues 4, 5, 6, 7 or 8,
- 35 c) determining the immunogenicity of the peptide fragments obtained in step b).
6. The method as claimed in claim 5, wherein step c) consists of an Elispot assay.

06673795-10000

7. A peptide compound which can be obtained using a method as claimed in one of claims 1 to 5, wherein it comprises a sequence of at least 8 consecutive amino acids of hsp70 which has at least one mutation or one  
5 modification with respect to the natural hsp70 sequence, and wherein it brings about a specific T response.
8. The peptide compound as claimed in claim 7, having at least 80% homology with the amino acids between  
10 positions 286 and 294 of hsp70.
9. The peptide compound as claimed in claim 8, wherein the amino acid at position 293 is preferably isoleucine, leucine, valine, alanine, glycine or phenylalanine, more particularly isoleucine.
10. The peptide compound as claimed in claim 9, which has at least the sequence SEQ ID No. 1 or SEQ ID No. 2.
11. The peptide compound as claimed in one of claims 7 to 10, wherein it comprises at least one element other than natural amino acids.
12. A DNA fragment encoding at least a peptide fragment of one of claims 7 to 11.
13. A vector for expressing a peptide fragment as claimed in one of claims 7 to 11, containing the DNA fragment of claim 12 fused to a promoter which is  
25 strong and effective in eukaryotic and/or in prokaryotic cells, in particular in human cells.
14. The expression vector as claimed in claim 13, also comprising one or more selection marker(s) and, optionally, one or more coding sequence(s) for factors  
30 which activate the immune defenses, such as cytokines and/or lymphokines.
15. The vector as claimed in either of claims 13 and 14, wherein it is a viral vector, a plasmid or a pseudovector.
16. A dendritic cell loaded with peptide compounds as claimed in one of claims 7 to 11.
17. A dendritic cell transformed with the expression vector as claimed in one of claims 13 to 15.

18. The dendritic cell as claimed in either of claims 16 and 17, wherein they belong to macrophages.

19. A pharmaceutical composition comprising a peptide compound, or a mixture of peptide compounds, as claimed 5 in one of claims 7 to 11 and a pharmaceutically acceptable vehicle.

20. The pharmaceutical composition as claimed in claim 19, wherein it also comprises one or more immunological adjuvants, in particular factors which are cytotoxic for tumors.

21. A pharmaceutical composition comprising an expression vector as claimed in one of claims 13 to 15 and a pharmaceutically acceptable vehicle.

22. A pharmaceutical composition comprising in  
15 particular a DNA fragment as claimed in claim 12 and a  
pharmaceutically acceptable vehicle.

23. A pharmaceutical composition comprising the cells as claimed in one of claims 16 to 18 and a pharmaceutically acceptable vehicle.

20 24. A combination product comprising at least one  
peptide compound as claimed in one of claims 7 to 11  
and at least one agent which induces cellular stress,  
for simultaneous or separate use, or for use spread out  
over time, intended for treating cancer.

25 25. The combination product as claimed in claim 24,  
wherein said agent is capable of inducing  
overexpression of heat shock proteins, in particular  
hsp70.

26. The combination product as claimed in claim 24,  
30 wherein said agent is an apoptosis inducer, selected in  
particular from DNA-damaging agents and glucocorticoid  
receptor ligands, or from pro-apoptotic second  
messengers.

27. The combination product as claimed in claim 24,  
35 comprising a viral vector which has a gene which  
encodes an enzyme for activating pro-apoptotic agents,  
in particular thymidine kinase.

**00000000000000000000**

28. The combination product as claimed in claim 24, in which the agent which induces cellular stress is selected from compounds which induce tumor hypoxia, in particular angiogenesis inhibitors.
- 5 29. The pharmaceutical composition as claimed in one of claims 19 to 23, or the combination product as claimed in one of claims 24 to 28, wherein it also comprises one or more immunological adjuvants, in particular agents which are cytotoxic for tumors.
- 10 30. The pharmaceutical composition as claimed in one of claims 19 to 23, or the combination product as claimed in one of claims 24 to 29, wherein it comprises a pharmaceutical vehicle which is compatible with IV, subcutaneous, oral or nasal administration.
- 15 31. The pharmaceutical composition as claimed in one of claims 19 to 23, or the combination product as claimed in one of claims 24 to 29, wherein it comprises a pharmaceutical vehicle selected from positively or negatively charged liposomes, nanoparticles or lipid emulsions.
- 20 32. The use of a peptide compound as claimed in one of claims 7 to 11 for manufacturing a medicinal product.
33. The use of a peptide compound as claimed in one of claims 7 to 11 for manufacturing a medicinal product intended for treating cancer.
- 25 34. The use of a peptide compound as claimed in one of claims 7 to 11 for manufacturing a medicinal product intended for immunization ex situ.
35. The use of a peptide compound as claimed in one of claims 7 to 11 for manufacturing a medicinal product intended for immunization in situ.
- 30 36. The use of a peptide compound as claimed in one of claims 7 to 11 for manufacturing a medicinal product intended for treating cancer, particularly solid tumors, especially carcinomas, melanomas, neuroblastomas and neck and head cancers, preferably renal carcinomas.
- 35


09673795-102000

37. The use of a peptide compound as claimed in one of claims 7 to 11 for increasing, in culture medium, the tumor CTL population and/or inducing the secretion by said CTLs of cytotoxic factors, such as for example IL-2, IFN- $\gamma$  or TNF.
38. The use of a peptide compound as claimed in one of claims 7 to 11 for manufacturing a medicinal product intended for stimulating the immune defenses, in particular so as to increase the tumor CTL population and/or induce the secretion by said CTLs of cytotoxic factors, such as for example IL-2, IFN- $\gamma$  or TNF.
39. The use as claimed in one of claim 32 to 38, in combination with radiotherapy.
40. The use as claimed in one of claim 32 to 39 for performing repeated immunization for the purpose of causing a breakdown of tolerance against the corresponding natural peptide (nonmutated) in a patient.
41. A method for producing an antibody which binds to an hsp70 mutant, in particular to the hsp70-2 I-293 mutant, comprising the steps consisting in:
- immunizing a mammal with a peptide compound as claimed in one of claim 7 to 11,
  - isolating a monoclonal antibody which binds to hsp70-2-293, particularly to hsp70-2 I-293, in an immunological assay.
42. A monoclonal antibody which binds to a mutated-hsp70 fragment, particularly to hsp70-2 I-293.
43. A method for detecting mutated hsp70, in particular the hsp70-2 I-293 mutation or modification, comprising the steps consisting in:
- bringing a sample taken from an individual into contact with a monoclonal antibody as claimed in claim 42,
  - allowing the formation of the antibody/mutated hsp70 complex, in particular of the antibody/hsp70-2-293 complex,




- c) detecting mutated hsp70 by means of a detectable label which is in the complex or which binds to the complex.
44. A diagnostic kit comprising in particular an antibody as claimed in claim 42, for detecting cancer.
- 5 45. A diagnostic kit comprising in particular an antibody as claimed in claim 42, for the prognostic of established cancer in an individual.
- 10 46. A pharmaceutical composition comprising in particular a monoclonal antibody as claimed in claim 42 and a pharmaceutically acceptable vehicle.

09673795-102000




Specific lytic activity of clone 11C2  
against the RCC-7 autologous cell line

FIG. 1




Secretion of TNF by the 11C2-CTL clone during stimulation with the RCC-7 autologous cell line

FIG. 2




Cytotoxicity of the 11C2 CTLs on multiple RCC allogenic cell lines

FIG. 3




Stimulation of the 11C2 CTL by the cells transiently cotransfected with the autologous HLA-A\*0201 cDNA and the A18 cDNA

FIG. 4




Location of the epitope region of HSP70  
recognized by the 11C2 CTL



Lysis by 11C2 CTL of the autologous cell line  
transformed with EBV and incubated with the peptides  
encoded by HSP70-2


FIG. 6



Induction of HLA-A2 expression on T2 cells by the  
HSP70-2 antigenic peptides

FIG. 7





Northern Blot Analysis

FIG. 8

09673795-102000


00020T\*56/EZ960

WO 99/54464

9/9

09/673795

PCT/FR99/00957



## DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first, and sole inventor (if only one name is listed below) or an original, first, and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**MUTATED PEPTIDE COMPOUNDS, DERIVED FROM hsp70, USEFUL IN CANCER IMMUNOTHERAPY** ✓

the specification of which ~~is~~ is attached and ~~or~~ was filed on **APRIL 22, 1999** as **United States Application Serial No. ~~or~~ PCT International Application No. PCT/FR99/00957** and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate or § 365(a) of any PCT International application(s) designating at least one country other than the United States, listed below and have also identified below, any foreign application(s) for patent or inventor's certificate, or any PCT International application(s) having a filing date before that of the application(s) of which priority is claimed:

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. 119
FRANCE ✓	98/05033 ✓	22/APRIL/1998 ✓	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> YES <input type="checkbox"/> NO

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

Application Number	Date of Filing

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) or § 365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application(s) and the national or PCT International filing date of this application:

Application Number	Date of Filing	Status (Patented, Pending, Abandoned)
PCT/FR99/00957	APRIL 22, 1999	Pending

I hereby appoint the following attorney and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: **FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER L.L.P.**, Douglas B. Henderson, Reg. No. 20,291; Ford F. Farabow, Jr., Reg. No. 20,630; Arthur S. Garrett, Reg. No. 20,338; Donald R. Dunner, Reg. No. 19,073; Brian G. Brunsold, Reg. No. 22,593; Tipton D. Jennings, IV, Reg. No. 20,645; Jerry D. Voight, Reg. No. 23,020; Laurence R. Heffler, Reg. No. 20,827; Kenneth E. Payne, Reg. No. 23,088; Herbert H. Mintz, Reg. No. 25,691; C. Larry O'Rourke, Reg. No. 26,014; Albert J. Santorelli, Reg. No. 22,810; Michael C. Elmer, Reg. No. 25,857; Richard H. Smith, Reg. No. 20,609; Stephen L. Peterson, Reg. No. 26,325; John M. Romary, Reg. No. 26,331; Bruce C. Zotter, Reg. No. 27,680; Dennis P. O'Reilly, Reg. No. 27,932; Allen M. Sokal, Reg. No. 26,595; Robert D. Bajefsky, Reg. No. 25,387; Richard L. Stroup, Reg. No. 28,478; David W. Hill, Reg. No. 28,220; Thomas L. Irving, Reg. No. 28,619; Charles E. Lipsey, Reg. No. 28,165; Thomas W. Winland, Reg. No. 27,605; Basil J. Lewis, Reg. No. 28,878; Martin I. Fuchs, Reg. No. 28,508; E. Robert Yoches, Reg. No. 30,120; Barry W. Graham, Reg. No. 29,924; Susan Haberman Griffen, Reg. No. 30,907; Richard B. Racine, Reg. No. 30,415; Thomas H. Jenkins, Reg. No. 30,857; Robert E. Converse, Jr., Reg. No. 27,432; Clair X. Mullen, Jr., Reg. No. 20,348; Christopher P. Foley, Reg. No. 31,354; John C. Paul, Reg. No. 30,413; Roger D. Taylor, Reg. No. 28,992; David M. Kelley, Reg. No. 30,953; Kenneth J. Meyers, Reg. No. 25,148; Carol P. Einaudi, Reg. No. 32,220; Walter Y. Boyd, Jr., Reg. No. 31,738; Steven M. Anzalone, Reg. No. 32,095; Jean B. Foidis, Reg. No. 32,984; Barbara C. McCurdy, Reg. No. 32,120; James K. Hammond, Reg. No. 31,964; Richard V. Burguljan, Reg. No. 31,744; Michael Jakes, Reg. No. 32,824; Dirk D. Thomas, Reg. No. 32,600; Thomas W. Banks, Reg. No. 32,719; Christopher P. Isaac, Reg. No. 32,815; Bryan C. Diner, Reg. No. 32,309; M. Paul Barker, Reg. No. 32,013; Andrew Chanho Sonu, Reg. No. 33,457; David S. Forman, Reg. No. 33,694; Vincent P. Kovalick, Reg. No. 32,867; James W. Edmondson, Reg. No. 33,871; Michael R. McGurk, Reg. No. 32,045; Joann M. Neith, Reg. No. 35,363; Gerson S. Panitch, Reg. No. 33,751; Chen M. Taylor, Reg. No. 33,216; Charles E. Van Horn, Reg. No. 40,266; and Linda A. Wadler, Reg. No. 33,218; and \_\_\_\_\_.

Please address all correspondence to **FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER L.L.P.**, 1300 I Street, N.W., Washington, D.C. 20005, Telephone No. (202) 406-4000.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full Name of First Inventor <b>TRIEBEL Frédéric</b>	Inventor's Signature <i>Frédéric</i>	Date <b>October 11, 2000</b>
Residence <b>10 rue Saint-Louis, F-78000 VERSAILLES, FRANCE</b>	Citizenship <b>French</b>	
Post Office Address <b>The same as residence</b>		

Listing of Inventors Continued on Page 2 hereof. ☒ Yes ☐ No

**FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER L.L.P.**

List of Inventors Continued From Page 1 hereof.

Full Name of Second Inventor <b>GAUDIN Catherine</b>	Inventor's Signature <i>C. Gaudin</i>	Date <b>October 11, 2000</b>
Residence <b>43 avenue des Iris, F-91600 SAVIGNY-SUR-ORGE, FRANCE</b>		Citizenship <b>French</b>
Post Office Address <b>The same as residence</b>		
Full Name of Third Inventor	Inventor's Signature	Date
Residence		Citizenship
Post Office Address		
Full Name of Fourth Inventor	Inventor's Signature	Date
Residence		Citizenship
Post Office Address		
Full Name of Fifth Inventor	Inventor's Signature	Date
Residence		Citizenship
Post Office Address		
Full Name of Sixth Inventor	Inventor's Signature	Date
Residence		Citizenship
Post Office Address		
Full Name of Seventh Inventor	Inventor's Signature	Date
Residence		Citizenship
Post Office Address		
Full Name of Eighth Inventor	Inventor's Signature	Date
Residence		Citizenship
Post Office Address		
Full Name of Ninth Inventor	Inventor's Signature	Date
Residence		Citizenship
Post Office Address		
Full Name of Tenth Inventor	Inventor's Signature	Date
Residence		Citizenship
Post Office Address		
Full Name of Eleventh Inventor	Inventor's Signature	Date
Residence		Citizenship
Post Office Address		

FINNEGAN, HENDERSON, FARABOW, GARRETT &amp; DUNNER L.L.P.

WO 99/54464

PCT/FR99/00957

## SEQUENCE LISTING

432 Rec'd PCT/PTO 20 OCT 2000

&lt;110&gt; INSTITUT GUSTAVE ROUSSY

<120> MUTATED PEPTIDE COMPOUNDS DERIVED FROM hsp70,  
USEFUL IN CANCER IMMUNOTHERAPY

&lt;130&gt; D17452

&lt;140&gt;

&lt;141&gt;

&lt;150&gt; FR 98 05033

&lt;151&gt; 1998-04-22

&lt;160&gt; 6

&lt;170&gt; PatentIn Vers. 2.0

&lt;210&gt; 1

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 1

Ser Leu Phe Glu Gly Ile Asp Ile Tyr

1

5

&lt;210&gt; 2

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

Ser Leu Phe Glu Gly Ile Asp Ile Tyr Thr

1

5

1

5

10

&lt;210&gt; 3

&lt;211&gt; 37

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 3

gggcaagctt ggactcagaa tctccccaga cgccgag

37

&lt;210&gt; 4

&lt;211&gt; 36

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 4

gccctctaga tctcagtcctc tcacaaggca getgtc

36

09/673795 10/2000

<210> 5  
<211> 30  
<212> DNA  
<213> Homo sapiens

<220>

<223> Probe HSP702A

<400> 5  
gggcaagctt agtctcagag cggagccaac 30

<210> 6  
<211> 30  
<212> DNA  
<213> Homo sapiens

<220>

<223> Probe HSP70-2B

<400> 6  
gccctctaga gtcccaacag tccacctcaa 30

Publ. No. 99/54464

<110> TRIEBEL, FREDERIC  
GAUDIN, CATHERINE

<120> MUTATED PEPTIDE COMPOUNDS, DERIVED FROM hsp70, USEFUL IN CANCER  
IMMUNOTHERAPY

&lt;130&gt; 03715.0069

<140> 09/673,795

<141> 2000-10-20

&lt;150&gt; PCT/FR99/00957

<151> 1999-04-22

<150> FR 98 05033

<151> 1998-04-22

&lt;160&gt; 8

&lt;170&gt; PatentIn Vers. 2.1

<210> 1

<211> 9

&lt;212&gt; PRT

<213> Homo sapiens

<400> 1

Ser Leu Phe Glu Gly Ile Asp Ile Tyr

1

5

<210> 2

<211> 10

&lt;212&gt; PRT

<213> Homo sapiens

<400> 2

Ser Leu Phe Glu Gly Ile Asp Ile Tyr Thr

1

5

10

<210> 3

&lt;211&gt; 37

<212> DNA

<213> Homo sapiens

<400> 3

gggcaagctt ggactcagaa tctccccaga cgccgag

37

<210> 4

<211> 36

<212> DNA

<213> Homo sapiens

<400> 4  
gccctctaga tctcagtcctc tcacaaggca gctgtc 36

<210> 5  
<211> 30  
<212> DNA  
<213> Homo sapiens

<220>  
<223> HSP702A probe

<400> 5  
gggcaagctt agtctcagag cggagccaac 30

<210> 6  
<211> 30  
<212> DNA  
<213> Homo sapiens

<220>  
<223> HSP70-2B probe

<400> 6  
gccctctaga gtccaacag tccacctcaa 30

<210> 7  
<211> 10  
<212> PRT  
<213> Homo sapiens

<400> 7  
Ser Leu Phe Glu Gly Ile Asp Phe Tyr Thr  
1 5 10

<210> 8  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 8  
Ser Leu Phe Glu Gly Ile Asp Phe Tyr  
1 5

00673795-102000